antibody-drug conjugates

Market Access
Six takeaways from JP Morgan 2024

Six takeaways from JP Morgan 2024

With another JP Morgan in the rearview mirror, it’s time to take stock of the announcements, the presentations, and, above all, the vibes.

News
GSK taps Hansoh for another cancer ADC candidate

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront